Navigation Links
Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease

roughout the duration of the 12-month study, or in the subsequent two years since the study formally ended.

About Neurologix

Neurologix, Inc. is a development-stage company engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system utilizing gene therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease, epilepsy and other neurodegenerative and metabolic disorders. Neurologix's core technology, "NLX," is currently in the clinical development stages, having recently been tested in a company-sponsored Phase I human clinical trial to treat Parkinson's disease.

Cautionary Statement Regarding Forward-looking Statements

This news release includes certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any futu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/1/2015)... 1, 2015 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... and commercialization of targeted antiviral therapies, announced today that ... Conference taking place in New York, NY ... Meridien Hotel. James Sapirstein , ... Company,s business during his live presentation and will be ...
(Date:7/1/2015)... July 1, 2015 Eli Lilly and Company (NYSE: ... second quarter of 2015 on Thursday, July 23, 2015. Lilly ... the investment community and media to further detail the company,s ... 9 a.m. EDT. Investors, media and the general public can ... link that will be posted on Lilly,s website at ...
(Date:7/1/2015)... , July 1, 2015 Precyse, a leader ... announced today that, as part of its long term ... to be acquired by investment firm Pamplona Capital Management ... investors, Altaris Capital Partners and NewSpring Capital, have approved ... has assisted nearly 5,000 healthcare facilities and systems across ...
Breaking Medicine Technology:ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 3
(Date:7/2/2015)... Spring, Md. (PRWEB) , ... July 02, 2015 , ... ... mark in his solo cross-country walk to raise awareness and money for the ... and expects to arrive at PHA’s headquarters near Washington, D.C. by mid-September. He left ...
(Date:7/2/2015)... ... July 02, 2015 , ... Healthpointe ... to the orthopedic and spine surgery team at their Anaheim clinic. Dr. Krishnareddy ... tendonitis. Along with the spine and spine surgery, Dr. Krishnareddy also specializes in ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... management consulting services to the federal government, has announced they are among nine ... Business Management Office Support Services (BMOSS) contract not to exceed $250 million. ...
(Date:7/2/2015)... ... 2015 , ... B. E. Smith, the only full-service leadership ... national chief executive officer recruitment for Indiana Blood Center in Indianapolis, ... E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/2/2015)... Arlington, VA (PRWEB) , ... July 02, 2015 , ... ... the enabler of enterprise collaboration across platforms and devices, today announced it was ... SaaS for its Citizen Connect Platform. The award, given out by the Government Technology ...
Breaking Medicine News(10 mins):Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4
... in Bamberg, Calhoun, Chester, Kershaw, Lancaster, Lexington, Orangeburg, Richland, Sumter ... ... and COLUMBIA, S.C., April 30 BlueCross,BlueShield of South Carolina and ... South Carolina Department of Health and Human Services,to offer Medicaid benefits ...
... Dividend, ACTON, Mass., April 30 Psychemedics,Corporation (Amex: ... for,the period ended March 31, 2008. The Company also ... shareholders of record as of June 6,2008 to be ... Company,s 47th,consecutive quarterly dividend., The Company,s revenue for ...
... Limited Oversight of Imports, and Gaps in,State Regulations ... Trust for America,s,Health (TFAH) released a new ... food safety system, including obsolete laws, misallocation of,resources, ... "Our goal should be reducing the number of ...
... site of most of the proteins which favour ... Patients with liver cirrhosis may develop serious coagulopathy ... bleeding tendency. Plasma levels of fragment D-dimer (D-dimer) ... finding of a high plasma D-dimer concentration in ...
... E capsule therapy on NAFLD and so it should be ... , This study, performed by a team led ... to be published on March 14, 2008, in the World ... proportions in children worldwide in this decade. NAFLD is recognized ...
... DIEGO, April 30 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ... results after the NASDAQ Global Market closes on Wednesday, ... and Chief,Executive Officer, and Robert E. Hoffman, Arena,s Vice ... call at 5:00 p.m.,Eastern Time (2:00 p.m. Pacific Time) ...
Cached Medicine News:Health News:BlueCross BlueShield of South Carolina and WellPoint Affiliate Receive State Approval for Ten South Carolina Counties 2Health News:BlueCross BlueShield of South Carolina and WellPoint Affiliate Receive State Approval for Ten South Carolina Counties 3Health News:Psychemedics Corporation Announces First Quarter Results 2Health News:Psychemedics Corporation Announces First Quarter Results 3Health News:Psychemedics Corporation Announces First Quarter Results 4Health News:Psychemedics Corporation Announces First Quarter Results 5Health News:Report Finds Food Safety System in Crisis 2Health News:Report Finds Food Safety System in Crisis 3Health News:Report Finds Food Safety System in Crisis 4Health News:How to manage Chinese obese children with non-alcoholic fatty liver disease? 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 3
This set offers the full range of Keeler magnifiers and telescopes....
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut...
... Featuring up to ... allows examination in the ... sections plus the option ... for corneal transillumination., ,Filters ...
Medicine Products: